Two Firsts In Post-Mensing Litigation

Law360, New York (December 9, 2011, 3:34 PM EST) -- In a post-Mensing world, plaintiffs — faced with almost certain dismissal of any claim based on labeling, promotion or warnings — are scrambling to re-define their claims against generic drug manufacturers.

They are most certainly looking for their port in a storm. We are keeping track of post-Mensing generic drug preemption decisions — an ever-growing list of dismissals of failure-to-warn claims.

Today, however, our focus is on how Mensing is being applied to some of plaintiffs’ “alternate” theories of liability. So we bring you two cases...
To view the full article, register now.